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Mesenchymal Stromal Cells (MSC) isolated from various tissues are under
investigation as cellular therapeutics in a wide range of diseases. It is appreciated that
the basic biological functions of MSC vary depending on MSC tissue source, however
in-depth comparative analyses between MSC isolated from different tissue sources
under good manufacturing practice (GMP) conditions is lacking.
Aims and Objectives
Human clinical grade, low purity islet (LPI) fractions are generated as a by-product of
islet isolation for transplantation. MSC isolates were derived from LPI fractions with the
aim to perform a systematic, standardised comparative analysis of these cells to
clinically relevant bone marrow-derived MSC (BM MSC).
Materials and Methods
We derived MSC isolates from LPI fractions and expanded them in platelet-lysate (PL)-
supplemented medium, or in commercially available defined xeno-free medium. We
compared doubling rate, phenotype, differentiation potential, gene expression, protein
production and immunomodulatory capacity of LPI to BM MSC.
Results and Conclusion
We show that MSC can readily be derived in vitro from the non-transplanted fractions
from islet cell processing (LPI MSC). LPI MSC grow stably in serum-free or PL-
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supplemented media and demonstrate in vitro self-renewal as measured by colony
forming unit assay (CFU-F). LPI MSC express similar patterns of chemokines and pro-
regenerative factors to BM MSC and importantly, are equally able to attract immune
cells in vitro and in vivo and suppress T cell proliferation in vitro. Additionally, we show
that LPI MSC can be expanded to therapeutically relevant doses at low passage under
GMP conditions and therefore represent an alternative source of GMP MSC with
functions comparable to BM MSC.
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Mesenchymal Stromal Cells (MSC) isolated from various tissues are under investigation as 
cellular therapeutics in a wide range of diseases. It is appreciated that the basic biological 
functions of MSC vary depending on MSC tissue source, however in-depth comparative 
analyses between MSC isolated from different tissue sources under good manufacturing 
practice (GMP) conditions is lacking.  
Aims and Objectives 
Human clinical grade, low purity islet (LPI) fractions are generated as a by-product of islet 
isolation for transplantation. MSC isolates were derived from LPI fractions with the aim to 
perform a systematic, standardised comparative analysis of these cells to clinically relevant 
bone marrow-derived MSC (BM MSC).  
Materials and Methods 
We derived MSC isolates from LPI fractions and expanded them in platelet-lysate (PL)-
supplemented medium, or in commercially available defined xeno-free medium. We 
compared doubling rate, phenotype, differentiation potential, gene expression, protein 
production and immunomodulatory capacity of LPI to BM MSC.  
Results and Conclusion 
We show that MSC can readily be derived in vitro from the non-transplanted fractions from 
islet cell processing (LPI MSC). LPI MSC grow stably in serum-free or PL-supplemented 
media and demonstrate in vitro self-renewal as measured by colony forming unit assay (CFU-
F). LPI MSC express similar patterns of chemokines and pro-regenerative factors to BM 
MSC and importantly, are equally able to attract immune cells in vitro and in vivo and 
suppress T cell proliferation in vitro. Additionally, we show that LPI MSC can be expanded 
4 
 
to therapeutically relevant doses at low passage under GMP conditions and therefore 
represent an alternative source of GMP MSC with functions comparable to BM MSC.  
 
Abbreviations:  
AD – Adipose 
B cell – B Lymphocyte 
BM – Bone Marrow 
CFU - Colony Forming Unit 
DM – Dulbecco’s Modified Eagle Medium 
DMPL – DMEM plus PL 
EMT - Epithelial Mesenchymal Transition  
FABP-4 - Fatty Acid Binding Protein-4 
GMP - Good Manufacturing Practice 
GvHD – Graft versus Host Disease 
IDO - Indoleamine, 2-3 Dioxygenase 
IEQ – Islet Equivalent 
IL-1β - Interleukin-1-beta  
IFN- - Interferon-gamma 
ISCT – International Society for Cellular Therapy 
LPI – Low Purity Islet Fraction 
MSC - Mesenchymal Stromal Cell 
NK cell – Natural Killer Cell 
PBMC - Peripheral Blood Mononuclear Cell 
PDL-1 - Programmed Death Ligand 1 
PGE-2 - Prostaglandin E2  
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PL – Platelet Lysate 
RT – Room Temperature 
SM – Stem MACSTM XF Complete medium 
SMPL – SM plus PL 
SMXF- STEM MACS MSC expansion medium XF 
SNBTS - Scottish National Blood Transfusion Service 
T cell – T lymphocyte 
T-1DM – Type-1 Diabetes Mellitus 
TGF- - Transforming Growth Factor Beta 
TNF- - Tumor Necrosis Factor Alpha 
TSG-6 – Tumour Necrosis Factor -Inducible Gene 6 
VEGF - Vascular Endothelial Growth Factor 






Mesenchymal stromal cells (MSC) are multipotent cells found in variable numbers in the 
majority of tissues. Their immunoregulatory, pro-regenerative and differentiation potential, 
coupled with their relatively ease of procurement has made them attractive as cellular 
therapeutics (1). To date, there are over 1300 registered clinical trials (ClinicalTrial.gov) 
using MSC isolated from a variety of tissues in a wide range of disease and transplant 
settings. Historically, the majority of the clinical data has been generated from bone marrow 
(BM)-derived MSC, therefore much of the understanding of MSC function relates to BM-
derived cells. While living donor-BM donation is well-established, BM aspirates contain 
relatively low numbers of MSC that require extensive expansion to reach therapeutic doses 
(2) and the ease of generating therapeutically relevant doses of functional MSC reduces with 
increasing donor age (3, 4). BM MSC expanded at large scale show a degree of phenotypic 
and functional variation over time (5). These passage-dependant functional and phenotypical 
changes may underlie an observed decline in in vivo function, - for example BM MSC are 
more efficacious when used at lower passage in patients with graft versus host disease 
(GvHD) (6). As a result, BM MSC may not be ideal for every therapeutic situation and 
therefore there has been a concerted effort to look for alternative tissue sources, including 
adipose tissue and umbilical cord (7-9). MSC isolated from different sources are not identical 
in their biological function, with differences including immune-suppressive ability and 
angiogenic potential (10-13), this is extremely important when considering MSC therapeutic 
capacity (13),  
When contemplating MSC therapeutic modes of action, it is likely that MSC anti-
inflammatory function works in concert with MSC tissue-building capacity. These functions 
are elaborated in part by chemokines, vital in attracting immune cells such as monocytes 
(CCL2) and neutrophils (CXCL2) (12); immune modulating factors such as prostaglandin E2 
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(PGE-2) (14) and indolamine 2,3-dioxygenase (IDO) (15); and a variety angiogenic factors 
including vascular endothelial growth factor (VEGF) and CXCL8 (13). These properties of 
MSC are amplified by licensing with various stimulatory factors including interferon gamma 
(IFN-γ), tumour necrosis factor alpha (TNF-α) and/or interleukin 1-beta (IL-1β). Response to 
these cytokines can be variable depending on the tissue source (16-18). We recently 
conducted a comparative analysis of adipose and umbilical cord-derived MSC for differential 
expression of a suite of chemokines, immune modulating and angiogenic factors (13). Anti-
inflammatory and pro-angiogenic phenotypes correlated with positive outcomes in a 
transplant model (13). These methods are yet to be applied to MSC derived from other 
tissues. 
Pancreatic-derived MSC have been described by a number of groups (18, 19). They can be 
isolated from the waste product of pancreatic islet transplantation. Islet transplantation is used 
to treat individuals with Type-1 diabetes mellitus (T-1DM) with unstable glycaemic control 
(20,21). It is an efficacious based treatment involving enzymatic dissociation of the donor 
pancreata under GMP conditions to release islets for transplantation (21). Highly pure islets 
are transplanted into the recipients, leaving a fractionated by-product of digested exocrine 
tissue and low purity islets - small numbers of islets plus attached exocrine tissue – (LPI).  In 
this study we investigated the potential of using the LPI fraction as a starting material for 
GMP-compliant manufacture of MSC. We determined that LPI material can be used to 
manufacture MSC under GMP conditions at scale (LPI MSC). LPI MSC expanded using 
GMP-compatible reagents were systematically evaluated for their pro-regenerative and 




Materials and Methods 
Tissues and blood samples 
Research protocols and adherence to donation and ethical consent specific to the tissues used 
in this study were regulated by the Scottish National Blood Transfusion Service (SNBTS) 
Research Sample Governance Committee. 
Non-transplantable LPI were collected from waste fractions of the pancreatic islet transplant 
process, following processing of donated organs for clinical transplant (20, 21). These tissues 
were made available for research following informed written consent and their use was 
governed under SNBTS sample governance reference numbers 12-16 and 15-21. Human 
volunteer-donor Buffy Coat was used as a source of peripheral blood mononuclear cell 
(PBMC) for T lymphocyte (T cell) responder assays and chemotaxis assays and were 
obtained from SNBTS blood processing under sample governance reference number 14-02.  
Human Platelet Lysate  
Platelet lysate (PL) supplement was produced by repeatedly freezing and thawing date-
expired Human Platelet packs (SNBTS) to -80°C for 12 hours and thawing at room 
temperature (RT). The freeze/thaw cycles were repeated 3 times. Upon final thaw, 10 platelet 
donation packs were pooled and centrifuged at 350g, before decanting the supernatants as 
50ml aliquots and storing at -40°C. 
Culture Medium 
LPI MSC were derived, maintained and compared in the following culture media; 1. DMPL- 
DMEM (Thermo Fisher Scientific), supplemented with Heparin (Leo Labs) at a final 
concentration of 2IU/ml, 1Non-essential Amino Acids (Thermo Fisher Scientific), 5% 
human platelet lysate. 2. SM- STEM MACS MSC expansion medium XF (SMXF) (Miltenyi 
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Biotec Ltd.). 3. SMPL- SMXF supplemented with 5% human PL. Unless stated otherwise, 
studies show LPI and BM MSC maintained in SMPL.  
Tissue Processing and Culture Initiation 
Pancreatic Material 
Waste LPI fractions were received from the SNBTS islet isolation lab. LPI was washed once 
in SMPL medium, centrifuged at 300g for 5 minutes and then cultured at 0.006ml/cm2 at 
37°C in 5% CO2 in SMPL medium. (e.g. 0.45mL LPI fraction in a T75 flask, plus 9.5ml 
SMPL medium). Explant outgrowth was assessed, and adherent cells were observed 
migrating from the explanted materials. The medium was carefully exchanged at day 7 and 
thereafter changed every 3-4 days. Cultures were observed and photographed using an EVOS 
Cell Imaging System (Thermo Fisher Scientific). Once the cultures had reached 80-90% 
confluence the cells were recovered with a 10 minute incubation at 37°C with 0.13ml/cm2 1 
 TrypLE Select (Thermo Fisher Scientific). To remove cell debris the material was passed 
through a 100μm cell strainer (Falcon). The cells were counted using a haemocytometer and 
designated as “passage 0”. These cells were either cryopreserved at 1106 / 2ml cryovial in 
Cryostor (CS10, Sigma Ltd) or re-cultured at a density of 3000 cells per cm2 in Corning 
CellBIND flasks. 
Intensification of MSC Manufacturing Density 
Five donations of LPI were processed at a higher re-seeding density of 5000 cells per cm2 in 
SM +/- PL medium only at passage 1 and passage 2. 
Bone Marrow MSC 
Existing stocks of BM MSC isolates were used in this study for comparison. These cell 




All media were changed twice per week. On reaching 80-90% confluence, cultures were 
collected as described above, the cell count and yield per flask determined and re-seeded at a 
density of 3000 cells per cm2 in Corning CellBIND flasks. Cells were expanded continually 
in culture until at least 3 passages of complete cycles of growth to confluence had been 
achieved after passage 0. Unless stated otherwise, LPI and BM MSC were used at P3 
throughout this study.  
Tri-lineage differentiation  
MSC were assessed for their differentiation capacity using the Human Mesenchymal Stem 
Cell Functional Identification Kit (R&D Systems). This kit contains all necessary 
differentiation supplements and the primary and secondary antibodies required for detection. 
The mature phenotype of adipocytes, chondrocytes and osteocytes were defined by the 
binding of antibodies against fatty acid binding protein-4 (FABP-4), aggrecan and osteocalcin 
respectively. Primary antibodies were detected using secondary antibodies specific to the 
primary antibody (Northern Lights 577-conjugated anti-goat – FABP-4, Northern Lights 557-
conjugated donkey anti-mouse – osteocalcin and Northern Lights 557-conjugated Donkey 
Anti-goat –aggrecan). Samples were imaged with a Zeiss epi-fluorescent microscope and 
prepared using Zeiss software.    
Flow Cytometry 
Cells were dissociated into a single cell suspension and washed twice in buffer comprising PBS 
/2mM EDTA /0.1% human serum albumin (flow buffer). For MSC phenotyping, cells were 
stained using antibodies at various concentrations (detailed in table S1) in a total volume of 
100ul for 15 minutes at 4°C. Cells were washed 1 in flow buffer and resuspended in 200μl 
of flow buffer for analysis. Voltages were set using fluorescence minus one controls. A 
11 
 
minimum of 10,000 events were collected. Flow cytometry analysis was performed using BD 
LSRFortessa (BD Biosciences) or MACS Quant and analysed with Flow Jo software (Treestar- 
Ashland, Oregon, USA).  
T cell suppression assay 
T cell suppression assays were carried out as previously described (13) using ratios of 
MSC:PBMC ranging from 1:2 to 1:16. 
Chemotaxis assay 
Whole white blood cells (WBC) were isolated from fresh buffy coat as detailed in 
supplemental material 1. MSC were seeded at 3000 cells/cm2 in DMPL and grown as a 
monolayer in 24 well plates (Corning). Once 80% confluence was reached, MSC were either 
left unlicensed, or licensed. Licensing of MSC was carried out by incubation of 80% 
confluent cultures in complete medium supplemented with 10ng/ml each, of IFN-γ, IL-1β and 
TNF-α (R&D systems). After 24 hours, all wells were washed twice with PBS to remove 
cytokine, then 600μl of fresh DMPL was added to all wells and left for a further 24 hours. 
5μm-pore inserts (Fisher Scientific) were placed into the wells on top of the MSC and 
5.5105 WBCs in 100μl of DMPL was placed into the insert. The transwell plate was 
incubated at 37oC for 3 hours before the inserts were carefully removed and discarded. 
Migrated cells were harvested by collecting the supernatant and washing wells thoroughly 
with PBS, ensuring the collection of loosely adherent cells. Cells were washed and prepared 
for flow cytometry using Antibodies detailed in table S1. CountBright beads (50μl), used as 
per manufacturer’s instructions (Life Technologies) were added for cell counting. 
Murine Air Pouch Model 
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A previously established air pouch model was used to assess in vivo leukocyte migration 
induced by transplantation of human MSC (35). (Details of husbandry, licenses and 
techniques in supplemental methods 2). 1106 unlicensed or licensed LPI or BM MSCs in 1 
ml of sterile PBS or sterile PBS alone (control animals) was injected into the air pouch 24 
hours after the last injection of air. Mice were sacrificed and cells collected as previously 
described (summarized in S2) after 24 hours. Each sample was split into two and stained for 
2 separate flow cytometry panels, one to identify mouse innate immune cells; and one to 
identify mouse adaptive immune cells; as detailed in table S1. 
Gene Expression 
LPI and BM MSC were plated at a density of 1105/cm2 in DMPL. Once MSC reached 80% 
confluence, MSC were licensed as previously described, or left as unlicensed controls. Cells 
were incubated for a further 24 hours, and then were harvested as above. Supernatants were 
frozen at -80°C for Luminex analysis of protein expression (see below). 
Expression of chemokine, cytokine, chemokine receptor and cytokine receptor genes were 
assessed using quantitative PCR and RT2 Profiler™ PCR Arrays Human Chemokines & 
receptors (Qiagen) as previously described (13).  
Protein Secretion 
The 24 hour conditioned media from identical samples used for transcript analysis were 
collected and analysed using a Luminex 100 analyser (Bio rad) and premixed magnetic multi-
analyte kits (R&D systems cat No. LXS-AHM-2) in accordance to the manufacturer’s 
instructions. All reagents and standards were included in the kit and prepared as outlined in 
the guidelines. Briefly, samples were diluted 2 fold with calibrator diluent (75μl in 75μl). 10 
μl of the pre-coated microparticle cocktail was added to each well of the 96 well microplates, 
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followed by either 50μl sample or 50μl standard, sealed and placed on an orbital shaker 
(0.12mm orbit at 800 ± 50rpm) for 2 hours at room temperature (RT). The plates were 
washed twice with 100 μl/well wash buffer and then incubated with 50 μl/well anti-biotin 
detector antibody for 1 hour at RT on the shaker (0.12mm orbit at 800 ± 50rpm). The plates 
were washed as before and 50 μl/well of streptavidin-phycoerythrin was added and incubated 
for 30 minutes at RT. Microparticles were re-suspended in 100 μl/well of wash buffer and 
immediately read on the Bio-Rad analyser. Each microparticle bead region was designated 
and doublets excluded as stated on the certificate of analysis.  
Statistics 
Graphs and statistical analysis were generated with GraphPad Prism 6. Unpaired T tests were 
used to compare LPI vs. BM material and Paired T test’s utilised when assessing statistical 
differences within one tissue source.  Significant differences are marked on individual figures 





Establishment of human LPI cultures in GMP -compliant medium  
In culture, LPI material initially presented as plastic-adherent islets, identified through 
positive dithizone staining (Fig. 1.a.ii), and islands of dithizone negative exocrine tissue (Fig. 
1.a.iii). Adherent, cobble-stone shaped cells grew out from the islets and exocrine tissue as a 
monolayer, with longer spindle-shaped cells at the outer edges of the monolayer (Fig. 1.a). 
Flow cytometric analysis of freshly isolated tissue (day 0), showed that the majority of cells 
were EPCAM +ve epithelial cells, and no CD90 and CD105+ve cells were detected (Fig. 
1.b.i). As cultures matured, EPCAM and MSC marker expression was mutually exclusive and 
the prevalence of CD105, CD90 and CD73 cells went from <1% to >90%, and EPCAM 
expressing cells went from >50% to <0.3% over a period of 16 days (Fig. 1.b.i-iv). At P0, the 
majority of cells were positive for MSC markers, where 95% of cells were vimentin +ve and 
<1% were EPCAM +ve (Fig. 1.b.iv).  
LPI derived cells could be reliably established in GMP-compliant media; DMPL, SM and 
SMPL, where doubling rate was consistent across all three passages (P1-P3) (Fig. 2.a). LPI 
MSC grown in SMPL however, returned significantly higher CFU-F at P2 and P3, compared 
to DMPL and SM (Fig 2.b). There were no differences in CFU-F between LPI MSC and BM 
MSC grown in in SMPL at any of the three passages assessed (Fig 2.c). LPI cells established 
in SMPL displayed a characteristic MSC-like phenotype through plastic adherence and 
spindle-shaped morphology, akin to that of BM derived MSC grown in SMPL (Fig. 3.a). LPI 
cultures also expressed all the relevant MSC markers including positive expression of CD73, 
CD90 and CD105 and no expression of CD45, CD19, CD11b, CD34, CD14 and CD31. This 
MSC surface marker expression was maintained and EPCAM expression was consistently 
lacking through all passages (P3-P5 illustrated fig.3.b.). LPI derived-cells expression levels 
of all the aforementioned markers were similar to BM MSC at P3 (Fig. 3.b). Finally, to 
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confirm that LPI-derived cells were MSC, LPI cultures were differentiated into the three 
classical lineages; bone, cartilage and adipose. Positive expression of FAB-4 (Fig.3.c.i), 
osteocalcin (Fig.3.c.ii) and aggrecan (Fig.3.c.iii) confirmed successful differentiation into all 
three lineages, thus LPI cultures were considered MSC-like cells and are referred to as LPI 
MSC throughout the text. 
LPI MSC and BM MSC express a range of immune modulatory and pro-regenerative 
factors  
To understand whether LPI derived MSC displayed therapeutically desirable regenerative and 
immunomodulatory potential, they were assayed for their transcriptional and protein 
expression of immune response modulating and pro-regenerative factors with and without 
licensing, and compared to BM MSC at the same passage (Fig. 4.a and b). Unlicensed LPI 
and BM MSC expressed similar transcriptional patterns of chemoattractant/inflammatory 
modulating molecules, with the exception of CX3CL1 (fractalkine) and IL-16, which were 
transcribed at marginally higher levels in the LPI MSC. Upon licensing, both MSC types 
uniformly upregulated the inflammatory regulators tumor necrosis factor-inducible gene 6 
(TSG-6) and IDO. Patterns in the transcript expression of the pro-angiogenic CXC 
chemokines were almost identical between LPI and BM MSC, where CXCL8 was the most 
highly transcribed pro-angiogenic gene in LPI and BM derived MSC, with or without 
licensing (Fig. 4.a.). Various monocyte (CCL2), macrophage (CCL4), dendritic cell 
(CCL20), and neutrophil chemoattractants (CXCL’s 1, 2, 3, 5, 6 & 8) were all upregulated 
upon LPI and BM MSC licensing (Fig. 4.a.). Conditioned media from the same cells used in 
transcriptional analyses were tested for a selection of pro-angiogenic and chemotactic factors.  
Secreted proteins from licensed LPI and BM MSC closely tracked the transcriptional 
observations, with high amounts of CCL2, CCL20 and CXCL8 detected in unlicensed MSC 
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supernatants which were markedly upregulated upon licensing. VEGF, a pro-angiogenic 
factor was also produced in moderate amounts by resting and licensed MSC from either 
source (Fig. 4.b.).  
Immune cell attraction profiles of LPI and BM MSC are comparable both in vitro and 
in vivo  
Chemotaxis assays were utilized to assess whether LPI and BM MSC were able to induce 
migration of immune cells. Unlicensed LPI MSC differed markedly from BM MSC in 
attracting significantly more CD45 +ve cells, specifically neutrophils and monocytes. Upon 
licensing, both LPI and BM MSC attracted neutrophils and monocytes, with little to no 
attraction of B lymphocytes (B cells), T cells, natural killer (NK) cells and eosinophils (Fig. 
5.a.). LPI MSC attracted proportionately more monocytes than BM MSC but this did not 
reach statistical significance. To establish if observed in vitro behaviors of LPI and BM MSC 
persisted in vivo, this analysis was extended to a murine air pouch model. In contrast to in 
vitro data, unlicensed LPI and BM MSC attracted similar total numbers of all immune cells, 
with no significant differences detected. As observed in vitro, licensing LPI and BM MSC 
resulted in a marked upregulation in the ability of MSC to induce migration of all immune 
cells. No significant differences in the total number of immune cells migrating towards 
licensed LPI or BM MSC were observed, with the exception of licensed BM MSC attracting 
significantly more NK cells than licensed LPI MSC. Notably, similar to in vitro migration 
data, neutrophils and monocytes made up the majority of migrating immune cells towards 
licensed or unlicensed LPI and BM MSC, however, the migration of moderate numbers of B 
cells, NK cells and eosinophils were also observed in vivo (Fig. 5.b).  
LPI MSC are potent suppressors of T cell proliferation 
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Next, suppression of T cell proliferation by LPI was assessed and compared to BM MSC. We 
first investigated the capacity of MSC to suppress T cell proliferation without licensing 
(Example analysis Fig 6.a). Either LPI or BM MSC strongly suppressed T cell proliferation at 
ratios of 1MSC:2 PBMC, and the effect titrated with reducing numbers of MSC (Fig.6.b). 
Suppression of proliferation by LPI MSC was significantly higher at 1:8 than with BM MSC. 
Given that strong suppressive effects were seen with unlicensed MSC, we further 
investigated the role that licensing plays in MSC-suppression of T cell proliferation. Overall, 
licensing MSC had no beneficial or detrimental effect on T cell suppression mediated by 
MSC compared to unlicensed MSC, and no significant differences were observed between 
LPI and BM MSC at any ratio tested (Fig.6.c).  
GMP-compliant method and density intensification - scale up for manufacturing 
To scale up for manufacturing, a suitable volume of LPI tissue and subsequent re-seeding 
densities of LPI MSC had to be determined. Initially, LPI tissue was tested at a density of 
0.006ml/cm2 or 0.03ml/cm2 (1ml or 5ml total LPI fraction per T175 flask in a total volume of 
35ml). Cells were more readily established using the lower seeding density of 0.006ml/cm2. 
(data not shown). Therefore, to model a complete manufacturing process, 1 ml of LPI tissue 
was seeded into a T175 (0.006ml/cm2), and thereafter re-seeded at 5000 cells/cm2. The 
median cell yield at P0 was 13106, with a range of cell yield between 72106 and 4.7106 
(Fig. 7.a). MSCs grown as described above reached median yields of 5200106 by P2 (Fig. 
7.a).  As waste tissue from a successful islet isolation ranges from 6mls to 22mls (Fig. 7.b), 
theoretical yields of LPI MSC at P2 could range from 37000106 (6mls) to 116000 106 
(22mls) (Fig. 7.c). Cells manufactured in this way maintained the CD45-ve HLA-DR-ve, 





In this study we have shown that LPI MSC culture can be easily initiated, and the cells can be 
expanded to therapeutic scale at low passage. We have extensively compared phenotype and 
function of LPI-derived MSC to BM MSC and show that LPI MSC share therapeutically 
relevant characteristics with BM MSC.  
Derivation of LPI-MSC 
MSC-like cells isolated from pancreatic tissue have been described by several groups (18, 
19), we sought to expand on this work to produce GMP-grade MSC cell populations, rather 
than to re-programme these cells e.g. into beta-like cells. In vitro expanded pancreatic MSC 
populations may arise from small numbers of resident MSC, or as a result of epithelial to 
mesenchymal transition (EMT) and has been explored elsewhere (22-25). The phenotypic 
changes of LPI isolates we have described in this study point to EMT as the principal 
mechanism underlying the derivation of LPI MSC cultures. We show that freshly isolated 
LPI tissue lacks cells expressing the mesenchymal markers CD105 and CD90, but is rich in 
EPCAM +ve cells. Over the 16 day in vitro expansion period to reach P0, EPCAM +ve cells 
gradually become positive for CD90 and CD105 followed by a reduction in EPCAM staining 
cells to <1% of the total population, which was maintained throughout subsequent passages. 
At P0 over 91% of cells express and the definitive mesenchymal marker vimentin. From P1 
onwards, the MSC express CD105, CD90 and CD73. It is therefore most likely the LPI-MSC 
manufacturing processes described in this study produces isolates of culture-induced MSC-
like cells as a result of in vitro EMT, although involvement of small populations of precursors 
cannot be entirely ruled out. 
Function and Phenotype 
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The ISCT criteria for definition of MSC (29) has underpinned all recent MSC research and 
the LPI MSC generated in this study met all of these criteria. Phenotype alone does not reveal 
whether MSC from different sources, or cultured using different methods have equal 
therapeutic capacity. We have recently reported that umbilical cord derived MSC when co-
transplanted with islets into diabetic mice have a greater benefit on glycaemic control versus 
adipose derived MSC (cultured identically) and that these MSC isolates differed widely in 
expression of genes important in immune-response and angiogenesis (13). Here, we took a 
similar standardised approach in our analysis to systematically compare LPI MSC to BM 
MSC to ensure that they share clinically applicable characteristics beyond basic phenotyping. 
Transcriptional analysis of more than 30 genes highlighted that LPI MSC express similar 
immune-modulatory, pro-angiogenic and chemotactic factors to BM MSC. BM and LPI MSC 
responded to licensing with an upregulation in a number of genes including the immune 
modulators TSG-6 (27) and IDO (28), the proangiogenic and neutrophil chemoattractants 
CXCL2 and CXCL8 (29, 30), and the monocyte chemoattractant (also pro-angiogenic) CCL2 
(31).  
We have shown that these transcribed genes translate into in vitro and in vivo activity of the 
MSC with similar patterns in protein secretion between LPI and BM MSC. In vitro, strong 
chemoattraction of myeloid cells was a function of licensed LPI and BM MSC. In vivo, 
unlicensed BM and LPI MSC both induced infiltration of neutrophils and monocytes into the 
injection site. This function was greatly amplified when MSC were licensed before injection. 
Recruitment of inflammatory cells may be an unexpected function of cells with proven anti-
inflammatory properties, however, recruitment of circulating monocytes has been shown to 
be critical for microvascular growth (32). Moreover, neutrophil recruitment is necessary for 
blood vessel formation in an in vivo angiogenesis model (33). The chemoattraction of 
immune cells towards MSC likely serves more than one purpose, extending beyond 
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angiogenesis to immunomodulation of these attracted immune cells, presumably altering the 
inflammatory environment. Here we show that BM and LPI MSC not only attract similar 
types and numbers of immune cells, they also express similar patterns of the 
immunomodulatory genes TSG-6, IDO and TGF-β whilst exerting similar capacity to 
suppress T cell proliferation.  The ability of MSC to attract immune cells and subsequently 
immunosuppress them is an important therapeutic mode of action of MSC which has been 
demonstrated in a model of GvHD (34). Treatment of GvHD is an area where LPI MSC may 
offer an advantage over BM MSC, as LPI MSC supressed T cell proliferation at lower T 
cell:MSC ratios, and attracted more myeloid cells in an unlicensed state. LPI MSC could also 
potentially be used in islet transplant recipients: MSC have been shown to enhance 
engraftment and function in experimental models (13). Patients routinely receive two islet 
grafts (20), hence MSC could be generated from the LPI of the first transplant and used 
subsequently as an MHC-matched accessory cell to support the second graft, with potentially 
reduced immune sensitization compared to third-party MSC. 
Manufacturing of LPI MSC 
Extending the applications of a donated pancreas beyond high purity islet transplantation to 
involve the manufacture of MSC from the LPI fraction would extend clinical application of 
the donated organ to potentially treat many patients. Recent registry data indicates >2600 
donated pancreata for islet processing (36) (North America, Europe and Australia) over a ten 
year period to 2015. LPI fractions are therefore routinely available from transplant centres 
and should be readily available for distribution to manufacturing centres. LPI-MSC grow 
rapidly, in xeno-free medium – a single T175 flask initially seeded with 1ml of LPI can 
generate 5.2109 cells after two in vitro passages, with theoretical yields from a single LPI 
fraction of 31.7109 – 116109. This would be sufficient MSC to manufacture 356-1303 
doses (based on 1106 per kg with a patient weighing 89kg). This compares favourably to 
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projected manufacturing yields for BM MSC under GMP conditions using a whole BM 
donation (20-37ml) and standard culture vessels (2,5): 6.6x109 at P2 and up to 6.3x109 at P1 
respectively. Manufacture of MSC, irrespective of source, at this scale would become 
impractical using standard culture vessels and would benefit from the use of bioreactors – not 
necessarily to increase yield (this is not guaranteed e.g. ref 37.), but for ease of handling and 
speed of processing. Manufacturing to very large scale may well not be required in a single 
centre - a single LPI fraction from a donated pancreas could therefore support manufacturing 
in a number of different centres from a single donation. Samples from a single isolation, in 
simple storage medium, are routinely distributed fresh from the SNBTS islet isolation lab 
around the UK to multiple centres, subject to appropriate consent. 
In summary, we have demonstrated that MSC, derived from low purity islets fractions (LPI), 
exhibit many of the ideal immune-responsive and pro-regenerative functions of MSC in vitro 
and in vivo. These cells are readily expanded from donated clinical-grade material that is 
currently an unused by-product of islet isolation, and we have demonstrated their successful 
manufacture using fully GMP-compliant materials to therapeutic dose at low passage. Further 






Fig.1. GMP MSC culture derivation from waste LPI fractions of the islet isolation process  
a. Phase contrast micrographs of cellular outgrowth from islands of tissue isolated from 
LPI fractions. 14 days in culture results in characteristic cobblestone-shaped cells 
emerging from dithizone stained islets (ii) and exocrine tissue (iii), forming spindle-
shaped MSC-like cells at edges. Scale bar represents 0.2mm.  
b. Three parameter flow cytometry analysis of MSC and epithelial markers in LPI 
fraction over time. Flow cytometry plots show an increase in cells expressing CD90, 
CD105 and CD73 and a decrease in EPCAM expressing cells over time. An overlay 
of EPCAM (left column) and CD90 (right columns) show that MSC and epithelial 
markers are mutually exclusive (i-iii). At P1, LPI isolates lack EPCAM expression 
and express CD90, CD105, CD73 and vimentin.  
 
Fig. 2. LPI MSC growth characteristics in GMP compliant media and comparison to BM 
MSC   
a. Mean population doubling time for LPI-derived MSC lines in 3 different GMP-
compliant media. Mean +/- SD n=7.  DMPL – DMEM 5% Platelet lysate, SM – 
StemMACS, SMPL – StemMACS 5% Platelet lysate. 
b. Colony forming unit scores for LPI-derived MSC grown in DMPL, SM and SMPL 
across 3 passages (p1-p3) with numbers of colonies obtained from plating 10 
cells/cm2 in CFU-F (n=5). 
c. Colony forming unit scores for LPI-derived MSC vs BM MSC (n=9), both grown in 
SMPL across 3 passages. Data presented as mean ± SD and significance marked 
where applicable, p<0.05, ** p<0.01, *** p<0.001.  
 
Fig. 3. Morphology, Surface marker expression and differentiation capability of LPI MSC 
a. LPI isolate at P1 showing plastic-adherent cells with spindle-like MSC morphology 
(i), similar to that of BM-derived MSC at P2 (ii). SM + PL medium. Scale bar 
represents 400μm. 
b. Representative phenotypes of LPI MSC at P3-P5 (top panels) compared to BM MSC 
at P3 (bottom panels). LPI MSC homogeneously express CD90, CD105 and CD73, 
showing similar MFI to BM derived MSC. >99% of LPI MSC lack expression of 
CD45, CD11b, CD31, CD34, CD19 and CD14. Lack of EPCAM expression by LPI 
MSC is maintained through passage.  
c. Fluorescence micrographs of Tri-lineage differentiation of LPI-derived MSC into 
Adipose, Bone and Chondrocyte lineages (FAB-4, Osteocalcin and Aggrecan 
respectively). Matched isotype controls shown in bottom left inserts. Scale bar 




Fig. 4. Gene and Protein expression of chemoattractant, pro-inflammatory and anti-
inflammatory genes in LPI and BM MSC 
a. Gene expression by resting and licensed MSCs. The expression of chemoattractant, 
and proangiogenic genes by resting (-) and licensed (+) LPI and BM MSC (P3) were 
measured by RT2 Profiler™ PCR Arrays. The expression of anti-inflammatory genes 
was measured using qRT PCR as indicated. In each case, the mean 2(-ΔCT) is plotted 
and heatmaps were generated using Heatmapper software 
(http://www2.heatmapper.ca/). Each group of genes was analysed separately. n>3<6 
donors. 
b. Mean levels of chemoattractant and proangiogenic proteins detected by Luminex 
assay in 24hr supernatants harvested from the cultures detailed above. Data represents 
total concentration of protein minus background levels of each protein found in 
medium. Analysed by Heatmapper software as above. n>3<6 donors. 
Fig. 5. In vitro and In vivo immune cell attraction of LPI and BM MSC 
a. In vitro chemoattraction of peripheral WBC. (i). Representative composition of WBC 
added to transwell insert at start of chemotaxis experiments. (ii). Migration of WBC 
to LPI or BM MSC in the unlicensed (-) or licensed (+) state. Data represents the total 
number of migrated cells minus the total number of background migrated cells and 
presented as mean ± SEM.  
b. In vivo airpouch model showing the total numbers of migrated immune cells into the 
airpouch containing licensed or unlicensed LPI or BM MSC. Data is presented as the 
total number of each migrated immune cell minus the total numbers in PBS injected 
control mice. Stacked bars represent mean ± SEM, n= 2 for each MSC donor and 5 
mice per group. 
Fig.6. Inhibition of T cell proliferation and requirement for IFN-γ licensing  
a. Representative dye dilution results measuring inhibition of T cell proliferation by LPI 
or BM MSC. Cells were grown in SMPL and assayed at P3 and cultured with Ef670-
stained PBMC. Ratios are PBMC:MSC at outset of culture.  
b. Comparative Inhibition of T cell proliferation by unlicensed LPI or BM MSC. Both 
MSC types inhibit proliferation and the effects titrate with reducing MSC numbers. 
Mean of 3 different LPI and 4 different BM lines grown in SMPL, ratios are 
PBMC:MSC.   
c. Comparative Inhibition of T cell proliferation by licensed LPI or BM MSC. Mean of 
3 different LPI and 4 different BM lines grown in SMPL, ratios are PBMC:MSC.  
 
Fig.7. Intensification of manufacturing with GMP reagents 
a. Total cell yields from 1ml of LPI tissue from P0 to P1 in GMP compliant medium. 
b. Total mls of transplanted tissue vs waste tissue in the GMP islet isolation process.  
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c. Predicted cell yields from the lowest volume of waste tissue (6ml) over 2 passages 
and the highest volume of waste tissue (22mls) over 2 passages.  
d. Flow cytometric analysis of LPI MSC grown using the intensified method 
demonstrating negativity for hematopoietic markers, and homogeneous expression of 
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S.1. WBC preparation.  
5mls of donor buffy coat was transferred into a 15ml centrifuge tube. Blood was spun at 300g 
for 40 minutes (0 break, 0 acceleration). The plasma layer was discarded and the remaining 
cells were washed with 1x red blood cell lysis solution (Miltenyi Biotec) for 7 minutes, after 
which cells were spun at 300g for 20 minutes (9 break, 9 acceleration). Supernatant was 
discarded and remaining cells were washed in 1xPBS. 5ml of buffy coat typically yielded 
1.5-2.5x108 WBCs. 
S.2. Air Pouch Model. 
For the air pouch, all animals were housed within the Biological Central Research Facility 
(University of Glasgow). All experiments received ethical approval and were performed 
under the auspices of a UK Home Office License. Project licence number: 70/ 8377, 
Procedure number: 10. All operators held appropriate personal home office licenses. 6 – 
week old C57BL/6 female mice were obtained from Charles River Europe and before any 
procedure was carried out, mice were given 7 days within the Biological Central Research 
Facility for adjustment and settling. After experimental procedures, at the age of 8 – week, 
mice were euthanised using a recognised Schedule 1 technique (CO2 followed by femoral 
artery exsanguination). 
Air pouches were generated as previously described (35). Briefly 3ml of sterile air was 
injected subcutaneously into the intracapsular area of the mouse to create an air pouch. After 
3 days, a top-up of 3 ml sterile air was injected into the air pouch. A third top up of 1ml 
sterile air was injected 2 days later and experimental material was injected 24 hours after the 
last air injection. Cells or PBS controls were left in the air pouch for 24 hours before mice 
were sacrificed. Immediately after sacrifice, 3ml of flow buffer was injected into the air 
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pouches of the mice and mice were gently shaken to allow the flow buffer to mix throughout 
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